Last reviewed · How we verify

NCT05320640

Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

Status unknown Phase 1, PHASE2 Last updated 11 April 2022
What this trial tests

Phase 1, PHASE2 trial testing Chidamide in Relapsed/Refractory Non-Hodgkin Lymphoma in 100 participants. Status unknown.

Timeline
30 March 2022
Primary endpoint
1 April 2024
1 April 2025

Quick facts

Lead sponsorChinese PLA General Hospital
PhasePhase 1, PHASE2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment100
Start date30 March 2022
Primary completion1 April 2024
Estimated completion1 April 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Chinese PLA General Hospital

Who can join

Adults 16 to 80, any sex, with Relapsed/Refractory Non-Hodgkin Lymphoma or Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I/II trial aims to evaluate safety and efficacy of Chidamide, Decitabine and Immune checkpoint inhibitors in relapsed/refractory Non-Hodgkin Lymphoma and advanced solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Current trends in sensitizing immune checkpoint inhibitors for cancer treatment.
    Wei J, Li W, Zhang P, Guo F, et al · · 2024 · cited 82× · PMID 39725966 · DOI 10.1186/s12943-024-02179-5
  2. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
    Zhao A, Zhou H, Yang J, Li M, et al · · 2023 · cited 81× · PMID 36797244 · DOI 10.1038/s41392-023-01342-6
  3. Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment.
    Sun Y, Hong JH, Ning Z, Pan D, et al · · 2022 · cited 58× · PMID 36120308 · DOI 10.3389/fphar.2022.932914
  4. Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics.
    Zhong F, Lin Y, Zhao L, Yang C, et al · · 2023 · cited 40× · PMID 37117649 · DOI 10.1038/s41416-023-02292-0
  5. Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition.
    Han R, Ling C, Wang Y, Lu L. · · 2023 · cited 23× · PMID 37716965 · DOI 10.1186/s12935-023-03051-0
  6. Intimate communications within the tumor microenvironment: stromal factors function as an orchestra.
    Cheng B, Yu Q, Wang W. · · 2023 · cited 22× · PMID 36600243 · DOI 10.1186/s12929-022-00894-z
  7. Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors.
    Liang Y, Wang L, Ma P, Ju D, et al · · 2023 · cited 21× · PMID 38077327 · DOI 10.3389/fimmu.2023.1308264
  8. Transcriptional regulation of cancer stem cell: regulatory factors elucidation and cancer treatment strategies.
    Zhang Z, Zhang Y. · · 2024 · cited 19× · PMID 38561775 · DOI 10.1186/s13046-024-03021-y

Verify or expand the search:

Other trials of Chidamide

Trials testing the same drug.

Other recruiting trials for Relapsed/Refractory Non-Hodgkin Lymphoma

Currently open trials in the same condition.

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05320640.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing